PMC:7335697 / 28571-29590 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T80","span":{"begin":147,"end":152},"obj":"Body_part"},{"id":"T81","span":{"begin":248,"end":253},"obj":"Body_part"},{"id":"T82","span":{"begin":346,"end":351},"obj":"Body_part"},{"id":"T83","span":{"begin":583,"end":588},"obj":"Body_part"}],"attributes":[{"id":"A80","pred":"fma_id","subj":"T80","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A81","pred":"fma_id","subj":"T81","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A82","pred":"fma_id","subj":"T82","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A83","pred":"fma_id","subj":"T83","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":"Our study suggests that, despite well-described risk factors for poor outcome of COVID-19 infection are highly represented in our cohort, COVID-19 liver transplant patients show a clinical course not necessarily more severe to that observed in non-liver transplant patients affected by COVID-19.25–27 Publications pooling patients with different organ transplanted reported worse outcomes (in-hospital case fatality rate 24%–27%).11 13 Another publication merging surveys from European and American centres with a smaller sample than our prospective study reported 9 deaths among 39 liver transplant patients.28 Like others, we find that male patients are more prone to develop ARDS29 and have a more severe outcome.25 Although highly frequent in our cohort, CV and metabolic comorbidities were not over-represented in patients with poor outcomes.25 26 History of previous or active cancer, such as being transplanted for HCC or having cancer at the moment of the COVID-19 diagnosis, was associated with a poor outcome."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T58","span":{"begin":147,"end":152},"obj":"Body_part"},{"id":"T59","span":{"begin":248,"end":253},"obj":"Body_part"},{"id":"T60","span":{"begin":346,"end":351},"obj":"Body_part"},{"id":"T61","span":{"begin":583,"end":588},"obj":"Body_part"}],"attributes":[{"id":"A58","pred":"uberon_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A59","pred":"uberon_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A60","pred":"uberon_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A61","pred":"uberon_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"Our study suggests that, despite well-described risk factors for poor outcome of COVID-19 infection are highly represented in our cohort, COVID-19 liver transplant patients show a clinical course not necessarily more severe to that observed in non-liver transplant patients affected by COVID-19.25–27 Publications pooling patients with different organ transplanted reported worse outcomes (in-hospital case fatality rate 24%–27%).11 13 Another publication merging surveys from European and American centres with a smaller sample than our prospective study reported 9 deaths among 39 liver transplant patients.28 Like others, we find that male patients are more prone to develop ARDS29 and have a more severe outcome.25 Although highly frequent in our cohort, CV and metabolic comorbidities were not over-represented in patients with poor outcomes.25 26 History of previous or active cancer, such as being transplanted for HCC or having cancer at the moment of the COVID-19 diagnosis, was associated with a poor outcome."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T220","span":{"begin":81,"end":89},"obj":"Disease"},{"id":"T221","span":{"begin":90,"end":99},"obj":"Disease"},{"id":"T222","span":{"begin":138,"end":146},"obj":"Disease"},{"id":"T223","span":{"begin":883,"end":889},"obj":"Disease"},{"id":"T224","span":{"begin":922,"end":925},"obj":"Disease"},{"id":"T225","span":{"begin":936,"end":942},"obj":"Disease"},{"id":"T226","span":{"begin":964,"end":972},"obj":"Disease"}],"attributes":[{"id":"A220","pred":"mondo_id","subj":"T220","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A221","pred":"mondo_id","subj":"T221","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A222","pred":"mondo_id","subj":"T222","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A223","pred":"mondo_id","subj":"T223","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A224","pred":"mondo_id","subj":"T224","obj":"http://purl.obolibrary.org/obo/MONDO_0007256"},{"id":"A225","pred":"mondo_id","subj":"T225","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A226","pred":"mondo_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Our study suggests that, despite well-described risk factors for poor outcome of COVID-19 infection are highly represented in our cohort, COVID-19 liver transplant patients show a clinical course not necessarily more severe to that observed in non-liver transplant patients affected by COVID-19.25–27 Publications pooling patients with different organ transplanted reported worse outcomes (in-hospital case fatality rate 24%–27%).11 13 Another publication merging surveys from European and American centres with a smaller sample than our prospective study reported 9 deaths among 39 liver transplant patients.28 Like others, we find that male patients are more prone to develop ARDS29 and have a more severe outcome.25 Although highly frequent in our cohort, CV and metabolic comorbidities were not over-represented in patients with poor outcomes.25 26 History of previous or active cancer, such as being transplanted for HCC or having cancer at the moment of the COVID-19 diagnosis, was associated with a poor outcome."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T329","span":{"begin":147,"end":152},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T330","span":{"begin":147,"end":152},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T331","span":{"begin":178,"end":179},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T332","span":{"begin":248,"end":253},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T333","span":{"begin":248,"end":253},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T334","span":{"begin":298,"end":300},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T335","span":{"begin":346,"end":351},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T336","span":{"begin":425,"end":427},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T337","span":{"begin":430,"end":432},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T338","span":{"begin":512,"end":513},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T339","span":{"begin":583,"end":588},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T340","span":{"begin":583,"end":588},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T341","span":{"begin":638,"end":642},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T342","span":{"begin":638,"end":642},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T343","span":{"begin":694,"end":695},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T344","span":{"begin":876,"end":882},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T345","span":{"begin":1004,"end":1005},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Our study suggests that, despite well-described risk factors for poor outcome of COVID-19 infection are highly represented in our cohort, COVID-19 liver transplant patients show a clinical course not necessarily more severe to that observed in non-liver transplant patients affected by COVID-19.25–27 Publications pooling patients with different organ transplanted reported worse outcomes (in-hospital case fatality rate 24%–27%).11 13 Another publication merging surveys from European and American centres with a smaller sample than our prospective study reported 9 deaths among 39 liver transplant patients.28 Like others, we find that male patients are more prone to develop ARDS29 and have a more severe outcome.25 Although highly frequent in our cohort, CV and metabolic comorbidities were not over-represented in patients with poor outcomes.25 26 History of previous or active cancer, such as being transplanted for HCC or having cancer at the moment of the COVID-19 diagnosis, was associated with a poor outcome."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T147","span":{"begin":638,"end":642},"obj":"Chemical"}],"attributes":[{"id":"A147","pred":"chebi_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/CHEBI_30780"}],"text":"Our study suggests that, despite well-described risk factors for poor outcome of COVID-19 infection are highly represented in our cohort, COVID-19 liver transplant patients show a clinical course not necessarily more severe to that observed in non-liver transplant patients affected by COVID-19.25–27 Publications pooling patients with different organ transplanted reported worse outcomes (in-hospital case fatality rate 24%–27%).11 13 Another publication merging surveys from European and American centres with a smaller sample than our prospective study reported 9 deaths among 39 liver transplant patients.28 Like others, we find that male patients are more prone to develop ARDS29 and have a more severe outcome.25 Although highly frequent in our cohort, CV and metabolic comorbidities were not over-represented in patients with poor outcomes.25 26 History of previous or active cancer, such as being transplanted for HCC or having cancer at the moment of the COVID-19 diagnosis, was associated with a poor outcome."}

{"project":"LitCovid-PubTator","denotations":[{"id":"759","span":{"begin":164,"end":172},"obj":"Species"},{"id":"760","span":{"begin":265,"end":273},"obj":"Species"},{"id":"761","span":{"begin":322,"end":330},"obj":"Species"},{"id":"762","span":{"begin":600,"end":608},"obj":"Species"},{"id":"763","span":{"begin":643,"end":651},"obj":"Species"},{"id":"764","span":{"begin":819,"end":827},"obj":"Species"},{"id":"765","span":{"begin":81,"end":89},"obj":"Disease"},{"id":"766","span":{"begin":90,"end":99},"obj":"Disease"},{"id":"767","span":{"begin":138,"end":146},"obj":"Disease"},{"id":"768","span":{"begin":286,"end":294},"obj":"Disease"},{"id":"769","span":{"begin":567,"end":573},"obj":"Disease"},{"id":"770","span":{"begin":678,"end":682},"obj":"Disease"},{"id":"771","span":{"begin":883,"end":889},"obj":"Disease"},{"id":"772","span":{"begin":936,"end":942},"obj":"Disease"},{"id":"773","span":{"begin":964,"end":972},"obj":"Disease"}],"attributes":[{"id":"A759","pred":"tao:has_database_id","subj":"759","obj":"Tax:9606"},{"id":"A760","pred":"tao:has_database_id","subj":"760","obj":"Tax:9606"},{"id":"A761","pred":"tao:has_database_id","subj":"761","obj":"Tax:9606"},{"id":"A762","pred":"tao:has_database_id","subj":"762","obj":"Tax:9606"},{"id":"A763","pred":"tao:has_database_id","subj":"763","obj":"Tax:9606"},{"id":"A764","pred":"tao:has_database_id","subj":"764","obj":"Tax:9606"},{"id":"A765","pred":"tao:has_database_id","subj":"765","obj":"MESH:C000657245"},{"id":"A766","pred":"tao:has_database_id","subj":"766","obj":"MESH:D007239"},{"id":"A767","pred":"tao:has_database_id","subj":"767","obj":"MESH:C000657245"},{"id":"A768","pred":"tao:has_database_id","subj":"768","obj":"MESH:C000657245"},{"id":"A769","pred":"tao:has_database_id","subj":"769","obj":"MESH:D003643"},{"id":"A770","pred":"tao:has_database_id","subj":"770","obj":"MESH:D012128"},{"id":"A771","pred":"tao:has_database_id","subj":"771","obj":"MESH:D009369"},{"id":"A772","pred":"tao:has_database_id","subj":"772","obj":"MESH:D009369"},{"id":"A773","pred":"tao:has_database_id","subj":"773","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Our study suggests that, despite well-described risk factors for poor outcome of COVID-19 infection are highly represented in our cohort, COVID-19 liver transplant patients show a clinical course not necessarily more severe to that observed in non-liver transplant patients affected by COVID-19.25–27 Publications pooling patients with different organ transplanted reported worse outcomes (in-hospital case fatality rate 24%–27%).11 13 Another publication merging surveys from European and American centres with a smaller sample than our prospective study reported 9 deaths among 39 liver transplant patients.28 Like others, we find that male patients are more prone to develop ARDS29 and have a more severe outcome.25 Although highly frequent in our cohort, CV and metabolic comorbidities were not over-represented in patients with poor outcomes.25 26 History of previous or active cancer, such as being transplanted for HCC or having cancer at the moment of the COVID-19 diagnosis, was associated with a poor outcome."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T132","span":{"begin":883,"end":889},"obj":"Phenotype"},{"id":"T133","span":{"begin":936,"end":942},"obj":"Phenotype"}],"attributes":[{"id":"A132","pred":"hp_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A133","pred":"hp_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Our study suggests that, despite well-described risk factors for poor outcome of COVID-19 infection are highly represented in our cohort, COVID-19 liver transplant patients show a clinical course not necessarily more severe to that observed in non-liver transplant patients affected by COVID-19.25–27 Publications pooling patients with different organ transplanted reported worse outcomes (in-hospital case fatality rate 24%–27%).11 13 Another publication merging surveys from European and American centres with a smaller sample than our prospective study reported 9 deaths among 39 liver transplant patients.28 Like others, we find that male patients are more prone to develop ARDS29 and have a more severe outcome.25 Although highly frequent in our cohort, CV and metabolic comorbidities were not over-represented in patients with poor outcomes.25 26 History of previous or active cancer, such as being transplanted for HCC or having cancer at the moment of the COVID-19 diagnosis, was associated with a poor outcome."}

{"project":"2_test","denotations":[{"id":"32571972-32361327-45345550","span":{"begin":682,"end":684},"obj":"32361327"},{"id":"T42192","span":{"begin":682,"end":684},"obj":"32361327"}],"text":"Our study suggests that, despite well-described risk factors for poor outcome of COVID-19 infection are highly represented in our cohort, COVID-19 liver transplant patients show a clinical course not necessarily more severe to that observed in non-liver transplant patients affected by COVID-19.25–27 Publications pooling patients with different organ transplanted reported worse outcomes (in-hospital case fatality rate 24%–27%).11 13 Another publication merging surveys from European and American centres with a smaller sample than our prospective study reported 9 deaths among 39 liver transplant patients.28 Like others, we find that male patients are more prone to develop ARDS29 and have a more severe outcome.25 Although highly frequent in our cohort, CV and metabolic comorbidities were not over-represented in patients with poor outcomes.25 26 History of previous or active cancer, such as being transplanted for HCC or having cancer at the moment of the COVID-19 diagnosis, was associated with a poor outcome."}

{"project":"LitCovid-sentences","denotations":[{"id":"T348","span":{"begin":0,"end":1019},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Our study suggests that, despite well-described risk factors for poor outcome of COVID-19 infection are highly represented in our cohort, COVID-19 liver transplant patients show a clinical course not necessarily more severe to that observed in non-liver transplant patients affected by COVID-19.25–27 Publications pooling patients with different organ transplanted reported worse outcomes (in-hospital case fatality rate 24%–27%).11 13 Another publication merging surveys from European and American centres with a smaller sample than our prospective study reported 9 deaths among 39 liver transplant patients.28 Like others, we find that male patients are more prone to develop ARDS29 and have a more severe outcome.25 Although highly frequent in our cohort, CV and metabolic comorbidities were not over-represented in patients with poor outcomes.25 26 History of previous or active cancer, such as being transplanted for HCC or having cancer at the moment of the COVID-19 diagnosis, was associated with a poor outcome."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T203","span":{"begin":81,"end":89},"obj":"SP_7"},{"id":"T204","span":{"begin":138,"end":146},"obj":"SP_7"},{"id":"T205","span":{"begin":147,"end":152},"obj":"UBERON:0002107"},{"id":"T206","span":{"begin":248,"end":253},"obj":"UBERON:0002107"},{"id":"T207","span":{"begin":286,"end":294},"obj":"SP_7"},{"id":"T208","span":{"begin":346,"end":351},"obj":"UBERON:0000062"},{"id":"T209","span":{"begin":567,"end":573},"obj":"GO:0016265"},{"id":"T210","span":{"begin":583,"end":588},"obj":"UBERON:0002107"},{"id":"T211","span":{"begin":766,"end":775},"obj":"GO:0008152"},{"id":"T212","span":{"begin":964,"end":972},"obj":"SP_7"},{"id":"T95259","span":{"begin":81,"end":89},"obj":"SP_7"},{"id":"T21118","span":{"begin":138,"end":146},"obj":"SP_7"},{"id":"T79220","span":{"begin":147,"end":152},"obj":"UBERON:0002107"},{"id":"T86294","span":{"begin":248,"end":253},"obj":"UBERON:0002107"},{"id":"T82663","span":{"begin":286,"end":294},"obj":"SP_7"},{"id":"T72850","span":{"begin":346,"end":351},"obj":"UBERON:0000062"},{"id":"T29456","span":{"begin":567,"end":573},"obj":"GO:0016265"},{"id":"T96044","span":{"begin":583,"end":588},"obj":"UBERON:0002107"},{"id":"T97283","span":{"begin":766,"end":775},"obj":"GO:0008152"},{"id":"T54217","span":{"begin":964,"end":972},"obj":"SP_7"}],"text":"Our study suggests that, despite well-described risk factors for poor outcome of COVID-19 infection are highly represented in our cohort, COVID-19 liver transplant patients show a clinical course not necessarily more severe to that observed in non-liver transplant patients affected by COVID-19.25–27 Publications pooling patients with different organ transplanted reported worse outcomes (in-hospital case fatality rate 24%–27%).11 13 Another publication merging surveys from European and American centres with a smaller sample than our prospective study reported 9 deaths among 39 liver transplant patients.28 Like others, we find that male patients are more prone to develop ARDS29 and have a more severe outcome.25 Although highly frequent in our cohort, CV and metabolic comorbidities were not over-represented in patients with poor outcomes.25 26 History of previous or active cancer, such as being transplanted for HCC or having cancer at the moment of the COVID-19 diagnosis, was associated with a poor outcome."}